Fig. 6
From: Humoral immune response after different SARS-CoV-2 vaccination regimens
Presence of virus-neutralising antibodies (VNA) against the SARS-CoV-2 variants of concern B.1.1.7 (alpha, filled circles) and B.1.617.2 (delta, empty circles) after the second immunisation. Sera from 26 age- and gender-matched individuals who received a heterologous (AZD1222/BNT162b2, n = 9) or a homologous vaccination scheme (AZD1222/AZD1222, n = 9; BNT162b2/BNT162b2, n = 8) were tested (see Table 1). An individual VNA titre > 1:10 was defined as neutralising in our Vero-cell-based virus-neutralisation test (cVNT). †The significance of the median VNA titre differences against B.1.1.7 and B.1.617.2 was calculated using the Wilcoxon test (**p < 0.01). ‡Comparison of the median VNA titre differences achieved with different immunisation schemes against B.1.617.2 (Kruskal-Wallis test; ns not significant; **p < 0.01; ****p < 0.0001)